| Genetic Technologies (NASDAQ: GENE) Establishes China Operations |
| |
|
Genetic Technologies (NASDAQ: GENE), a provider of world-leading genetic risk assessment test products, announced that it has now established its Asian operations within the Hainan Resort Software Community (“HRSC”) Free Trade Zone.
Why It Matters: Participants in the Hainan Medical Pilot Zone gain access to the $925 billion Chinese healthcare market. As a part of the HRSC, Genetic Technologies will receive assistance in obtaining China FDA approval for the Company’s new and growing portfolio of genetic risk assessment tests, dramatically fast-tracking the ‘pathway to sales’ process. In addition, as a part of the HRSC, the Company can take advantage of significant tax benefits, subsidies, and facilitated investment.
Key Quote: “The establishment of operations in Hainan China is a significant step to advance the adoption of genetic risk assessment tests in China and in due course other parts of Asia. We are grateful for the support we have received from HRSC to date and acknowledge their commitment to continue to work with GTG to provide a meaningful contribution to the Healthy China 2030 Policy.” Dr. Paul Kasian, Chairman & CEO
Disclosure
Genetic Technologies (NASDAQ: GENE) is a client of RedChip Companies, Inc. GENE agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.
|
|
| |
|
| GSRX Industries (OTCQB: GSRX) Announces Preferred Partnership with Social Engagement Platform Buzznog |
| |
|
GSRX Industries’ (OTCQB: GSRX) Pure and Natural CBD subsidiary entered into a preferred partnership and advertising agreement with Buzznog, a direct-to-fan social media platform for live events and activations.
Why It Matters: Under terms of the agreement, Pure and Natural will become Buzznog’s premier CBD partner. Buzznog provides powerful solutions for established and emerging artists, festivals, and brands. In addition to its cutting-edge technologies for live events, music releases, and fan engagement Buzznog creates hyper-focused targeted initiatives to deliver the right content at the right time to the right audience.
Key Quote: “This partnership with Buzznog will allow us to introduce our diverse Pure & Natural line of high-quality non-THC CBD products to fans of some of the biggest names in entertainment. Buzznog is tops in fan engagement and we can’t wait to make Pure & Natural part of their universe.” Les Ball, CEO
Disclosure
GSRX Industries (OTCQB: GSRX) is a client of RedChip Companies. RedChip Companies, Inc. received 1,000,000 registered shares of GSRX for consulting services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying.
|
|
| |
|
| RedChip Initiates Coverage of Level Brands (NYSE American: LEVB) with $10 Price Target |
| |
|
RedChip initiated research coverage of Level Brands (NYSE American: LEVB) last week, with a price target of $10 per share.
Level Brands owns and operates the nationally recognized consumer cannabidiol (CBD) brand cbdMD, whose current products include CBD gummies, CBD tinctures, CBD topicals, CBD bath bombs, CBD oils, and CBD pet products.
Since commencing sales in January 2018, cbdMD generated approximately $7.5 million in total net sales for calendar 2018. Sales increased sequentially throughout calendar 2018, with net sales of $580,000, $1,618,000, $1,696,000 and $3,625,000, for the quarters ending March 31, 2018, June 30, 2018, September 30, 2018, and December 31, 2018, respectively.
To view the full RedChip Research Report for Level Brands, please visit: www.levbinfo.com/LEVB_Research.pdf
Disclosure
Level Brands (NYSE American: LEVB) is a client of RedChip Companies. LEVB agreed to pay RedChip a monthly cash fee of between $5,000 and $15,000, and 5,000 shares of Rule 144 stock for RedChip investor awareness services. Additionally, the CEO of RedChip Companies owns 13,500 shares of LEVB.
|
|
| |
|
| Small-Caps: An Important Gauge of Broad Market Health |
| |
|
The Russell 2000 is up 17.5% year-to-date, and the benchmark index’s recent price action could be an important tell for the broader market over the next several months.
“While the Russell 2000 small-cap index has lagged the major averages, still down more than 10 percent from its September highs, market watchers say its next move will be critical to where stocks go in the next few months,” reports CNBC.
|
|
| |
|
| MYnd Analytics (NASDAQ: MYND) CEO to Present at ThinkEquity Conference in New York City |
| |
|
MYnd Analytics (NASDAQ: MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced that Patrick Herguth, Chief Executive Officer, is scheduled to present at the ThinkEquity Conference on Thursday, May 2, at 11:00 AM Eastern. The conference will be held at The Mandarin Oriental Hotel in New York City.
The Backstory: MYnd Analytics, with its wholly owned subsidiary Arcadian Telepsychiatry Services, LLC, is a technology-enabled telepsychiatry and teletherapy company that provides enhanced access to behavioral health services, improves patient outcomes, and helps lower the costs associated with behavioral health issues. The MYnd Psychiatric EEG Evaluation Registry (PEER) is a predictive analytics decision support tool that helps physicians reduce trial and error treatment for behavioral health conditions. PEER provides the physician a personalized care plan with recommended treatment options based on a patient’s unique brain markers, reducing treatment time and treatment costs. Arcadian Telepsychiatry Services, LLC provides a suite of complementary telemedicine services that can be combined with PEER, including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. MYnd’s customers include major health plans, health systems, and community-based organizations. To read more about the benefits of this patented technology for patients, physicians and payers.
Disclosure
MYnd Analytics, Inc. (NASDAQ: MYND) is a client of RedChip Companies, Inc. MYND agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services.
|
|
| |
|
| Immuron (NASDAQ:IMRN) Sales Surge by 66% in 3Q of FY19 |
| |
|
• Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending March 31, 2019.
• In Australia Q3 sales of Travelan® surged ahead, growing 73% YoY.
• In the US Q3 sales of Travelan® were similarly strong, growing 60% YoY.
• During Q3 FY19, Immuron received their first purchase order for Canada, marking the re-entry of Travelan® into this market of keen travelers.
Key Quote: “Our concerted focus on expanding sales growth of Travelan® within existing markets, coupled with our re-entry into Canada, puts us in a strong position for continued growth.” Dr. Gary S. Jacob, CEO of Immuron
The Backstory: Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one commercial asset generating revenue. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders, and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection. Immuron’s lead clinical candidate, IMM-124E, is presently in Phase II trials in Severe Alcoholic Hepatitis (SAH) and Pediatric Nonalcoholic Fatty Liver Disease (NAFLD). The company now has plans to develop a U.S. registration dossier for IMM-124E for Travelers’ Diarrhea. Immuron’s second clinical-stage asset, IMM-529, targets Clostridium difficile Infections (CDI), and is presently in a clinical trial in CDI patients. These products together with the Company’s other preclinical immunotherapy pipeline products currently under development targeting immune-related and infectious diseases are anticipated to meet pressing needs in the global immunotherapy market.
Disclosure
Immuron Ltd. (NASDAQ: IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for (3) months of investor awareness services.
|
|
| |
|
| Catasys (NASDAQ: CATS) Appoints Healthcare Industry Leader Carol Murdock to Newly Created Chief Commercial Officer Role |
| |
|
Catasys (NASDAQ: CATS) a leading AI and technology-enabled healthcare company, today announced the appointment of Carol Murdock as Chief Commercial Officer. She will lead Business Development, Account Management, Marketing and Corporate Communications, reporting to Mr. Terren Peizer, Chairman and CEO.
Ms. Murdock joins the Company with over 30 years of healthcare experience in market strategy and business development, where her managed care, technology and engagement expertise has helped customers lower cost and improve quality of care.
Most recently, she served as the Chief Marketing Officer of Healogics, the nation’s largest operator of outpatient wound care centers, where she launched a data science team responsible for publishing outcomes from the world’s largest wound care database.
Key Quote: “I am pleased to welcome Carol in the newly created role of Chief Commercial Officer. She will be pivotal in driving our continued rapid growth and expansion, leveraging her more than 30 years of diverse healthcare experience, particularly as we broaden our healthcare platform longer term.” Terren Peizer, Chairman and CEO of Catasys
The Backstory: Catasys harnesses proprietary big data predictive analytics, artificial intelligence and telehealth, combined with human interaction, to deliver improved member health and validated outcomes and cost savings to health plans. Our mission is to help improve the health and save the lives of as many people as possible.
Catasys' integrated, technology-enabled OnTrak solution--contracted with a growing number of national and regional health plans--is designed to treat members with behavioral conditions that cause or exacerbate co-existing medical conditions such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure, which result in high medical costs.
Catasys has a unique ability to engage these members, who do not otherwise seek behavioral healthcare, leveraging proprietary enrollment capabilities built on deep insights into the drivers of care avoidance.
Disclosure
Catasys (NASDAQ: CATS) is a client of RedChip Companies, Inc. CATS agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
|
|
| |
|
| |
| Quote of the Week |
| |
"Don't put too much money in any one stock, spread it out, you never know which ones will be your big winner."
- Buzz Heidkte, Owner MidSouth Investor Fund |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
|
